At close: December 19 at 8:09:52 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-77,980.0000
-82,025.0000
-77,514.0000
-30,196.0000
-5,382.0000
Investing Cash Flow
-87.0000
-414.0000
-2,712.0000
-22,214.0000
360.0000
Financing Cash Flow
124,695.0000
2,560.0000
47,804.0000
192,341.0000
75,447.0000
End Cash Position
188,978.0000
121,136.0000
201,015.0000
233,437.0000
93,506.0000
Capital Expenditure
-87.0000
-414.0000
-2,712.0000
-22,214.0000
--
Issuance of Capital Stock
--
--
47,329.0000
189,825.0000
75,191.0000
Free Cash Flow
-78,067.0000
-82,439.0000
-80,226.0000
-52,410.0000
-5,382.0000
12/31/2020 - 9/11/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALT1.MX Altimmune, Inc.
170.00
0.00%
ENVB Enveric Biosciences, Inc.
0.3284
+0.74%
DBVT DBV Technologies S.A.
3.0500
-2.24%
SLXN Silexion Therapeutics Corp
2.4200
+13.08%
ELAB Elevai Labs Inc.
2.3500
+9.30%
RNAZ TransCode Therapeutics, Inc.
3.8500
-1.79%
HRTX Heron Therapeutics, Inc.
1.5300
-2.55%
APLT Applied Therapeutics, Inc.
1.0200
-5.56%
SNTI Senti Biosciences, Inc.
3.9800
-0.75%
ENSC Ensysce Biosciences, Inc.
7.95
+30.97%